Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Braavos Investment Advisers is a London-based venture capital firm founded to invest in companies rooted in scientific breakthroughs. Established with a focus on Oxford-origin and Oxford-linked science businesses, Braavos aims to support the commercialization of innovative technologies that can transform industries. The firm manages over $500 million in assets under management (AUM) and has a portfolio that spans various sectors, including biotech, healthcare, AI, climate technology, and quantum computing.
Since its inception, Braavos has positioned itself as a key player in the venture capital landscape, particularly in the UK. The firm actively seeks to partner with founders who are building technically challenging and research-intensive companies. Its investment strategy emphasizes deep tech, life sciences, and advanced imaging, reflecting a commitment to supporting the growth of transformative businesses.
Located at 24 Grosvenor Street, London, Braavos Investment Advisers has established a reputation for its strategic guidance and access to a specialized network. The firm’s notable milestones include participation in significant funding rounds for companies like OXCCU and Salience Labs, showcasing its active role in the startup ecosystem.
Braavos Investment Advisers focuses on investing in early-stage through growth companies that are founded on scientific innovation. The firm targets sectors such as biotech, healthcare, AI, climate technology, energy, quantum computing, diagnostics, and synthetic biology. Its investment strategy is designed to identify opportunities in these fields, particularly those that involve deep tech and life sciences.
The firm typically engages with companies at various stages, including Seed, Series A, Series B, and Growth Equity. Although specific check sizes are not disclosed, Braavos is known for its substantial financial backing, which is complemented by strategic guidance and access to a specialized network. The firm emphasizes the importance of partnering with technically adept founders who possess a credible path from research to commercial scale.
Braavos Investment Advisers is particularly adept at assisting companies with long development timelines and substantial technical risks. The firm provides board-level involvement to help portfolio companies navigate technical and regulatory challenges while facilitating follow-on funding and partnerships.
Braavos Investment Advisers has built a diverse portfolio of companies that exemplify its focus on scientific breakthroughs. Notable portfolio companies include:
This portfolio reflects Braavos' commitment to supporting companies that are not only innovative but also have the potential to make significant impacts in their respective fields.
Andre Crawford-Brunt serves as the Founder and General Partner of Braavos Investment Advisers. He has extensive experience in technology and biotechnology investments, having previously spent over 20 years at Deutsche Bank, where he held the position of Managing Director and Global Head of Equity Trading. Crawford-Brunt is also a board member of several companies, including Oxford Sciences Innovations and PQShield.
Olwethu Tomtala CA(SA) is a team member at Braavos, although specific details about his role and focus are not verified in available sources.
Raeez Omar CA(SA) is another team member listed on LinkedIn, but further information regarding his role is not confirmed.
Laksh Aithani is also part of the Braavos team, with his specific responsibilities not detailed in the available sources.
Attentia Limited is listed as an LLP designated member, appointed on January 31, 2026, indicating a corporate member rather than an individual investing partner.
To pitch Braavos Investment Advisers, founders should use the contact form available on their website at braavos.uk. It is essential to include a comprehensive pitch deck that outlines the technology, market opportunity, and team qualifications. While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's focus on scientific innovation.
Warm introductions are preferred, especially from individuals within Braavos' network or from other founders in their portfolio. This can enhance the chances of receiving a timely response and establishing a meaningful connection with the firm.
In September 2025, OXCCU announced a successful £20.75M Series B funding round, with Braavos continuing as an investor. This round is aimed at scaling the company's technology for converting waste carbon into sustainable aviation fuel.
In February 2025, Salience Labs closed a $30M Series A funding round, with Braavos participating as a key investor. This funding will support the development of optical switches for AI datacenter infrastructure.
In January 2023, Oxford Ionics raised £30M in Series A funding, co-led by Braavos Investment Advisers, to advance its trapped-ion quantum computing technology.
What are Braavos Investment Advisers' investment criteria?
Braavos primarily invests in companies that are founded on scientific breakthroughs, focusing on sectors such as biotech, healthcare, AI, climate technology, and quantum computing. The firm seeks to partner with technically adept founders who have a credible path from research to commercial scale.
How can I apply or pitch to Braavos?
Founders can pitch their ideas through the firm's website at braavos.uk. It is advisable to include detailed information about the technology, market potential, and the founding team in the pitch deck.
What makes Braavos different from other venture capital firms?
Braavos distinguishes itself by its strong focus on scientific innovation and its commitment to supporting companies with long development timelines and substantial technical risks. The firm provides not only capital but also strategic guidance and access to a specialized network.
What is the geographic scope of Braavos' investments?
Braavos primarily focuses on investments in the United Kingdom, particularly in companies linked to Oxford University and its research ecosystem.
What is Braavos' approach to post-investment involvement?
The firm is actively involved with its portfolio companies at the board level, helping them navigate technical and regulatory challenges while facilitating follow-on funding and partnerships.
What is the typical fund size or check size for Braavos?
While specific check sizes are not disclosed, Braavos manages over $500 million in assets under management, indicating a capacity for substantial investments across its portfolio.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.